{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:50:45Z","timestamp":1791615045608,"version":"4.3.4"},"reference-count":29,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Korean government","doi-asserted-by":"publisher","award":["2020R1F1A1072449"],"award-info":[{"award-number":["2020R1F1A1072449"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"Korean government","doi-asserted-by":"publisher","award":["RS-2024-00346434"],"award-info":[{"award-number":["RS-2024-00346434"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"Korean government","doi-asserted-by":"publisher","award":["2025-16069136"],"award-info":[{"award-number":["2025-16069136"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2020R1I1A1A01067800"],"award-info":[{"award-number":["2020R1I1A1A01067800"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Education","award":["2026-ANCHOR-10-006"],"award-info":[{"award-number":["2026-ANCHOR-10-006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of adults globally; its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), has limited pharmacological options beyond the recently approved resmetirom. The statin\u2013ezetimibe combination, widely co-prescribed for dyslipidemia in patients with MASH, significantly reduces hepatic fat versus statin monotherapy in the ESSENTIAL randomized trial, yet macrophage-driven mechanisms linking this lipid-lowering combination to hepatic inflammation and fibrosis remain poorly characterized. We investigated these mechanisms using in vivo and in vitro approaches. Methods: Male C57BL\/6 mice (n = 6\/group; 6 groups) received a high-fat diet (HFD; 45% kcal) plus thioacetamide (TAA; 300 mg\/kg twice-weekly, 8 weeks) to establish MASH with advanced fibrosis. Simvastatin (5 mg\/kg) and\/or Ezetimibe (10 mg\/kg) were added to the diet for 4 weeks. Blinded hepatic histology (H&amp;E, Picrosirius red, Oil Red-O), qPCR, immunohistochemistry, and Western blot were performed. Macrophage polarization and NF-\u03baB nuclear translocation were assessed in RAW 264.7 cells and thioglycolate-elicited peritoneal macrophages by flow cytometry and immunofluorescence. Results: Combination therapy significantly reduced steatosis, inflammation, and fibrosis versus HFD-TAA controls. Pro-inflammatory (IL-1\u03b2, IL-6, TNF-\u03b1, iNOS) and fibrosis-related (collagen-I, \u03b1-SMA, TGF-\u03b21) markers were markedly suppressed (p &lt; 0.01). In vitro, the combination reduced the proportion of iNOS+ macrophages to approximately 50% of the LPS control (normalized to each experiment), although statistical significance was not reached; monotherapies showed weaker and variable trends and inhibited NF-\u03baB p65 nuclear translocation in cultured macrophages (Holm-adjusted p &lt; 0.01); MAPK signaling was not significantly altered under the present conditions. Anti-fibrotic effects were consistent with a macrophage-mediated mechanism, with no direct stellate cell suppression observed by LX-2 assays. Conclusions: Statin\u2013Ezetimibe combination exerts anti-inflammatory and anti-fibrotic effects in a multi-hit murine model of MASH with advanced fibrosis associated with macrophage NF-\u03baB inhibition in vitro and with reduced hepatic inflammatory signaling in vivo. These findings provide mechanistic rationale for the hepatic benefits of this widely used regimen in MASH patients with dyslipidemia, supporting its evaluation as a drug-repurposing strategy.<\/jats:p>","DOI":"10.3390\/cells15181700","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:38Z","timestamp":1789981298000},"page":"1700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statin\u2013Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-\u03baB Inhibition"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-3517","authenticated-orcid":false,"given":"Seul Ki","family":"Han","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-3810","authenticated-orcid":false,"given":"Jin Suk","family":"Lee","sequence":"additional","affiliation":[{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Su Jung","family":"Park","sequence":"additional","affiliation":[{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Mitohormesis Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Mi Ra","family":"Lee","sequence":"additional","affiliation":[{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Yu Jin","family":"Yi","sequence":"additional","affiliation":[{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3937-2222","authenticated-orcid":false,"given":"Kangchan","family":"Choi","sequence":"additional","affiliation":[{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Soon Koo","family":"Baik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-2206","authenticated-orcid":false,"given":"Moon Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"},{"name":"Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-050324-124753","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Metabolic Dysfunction\u2013Associated Steatohepatitis\u2013Related Fibrosis: Therapeutic Options and Approaches to Treatment","volume":"77","author":"Tincopa","year":"2026","journal-title":"Annu. Rev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in Adults: A Review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1001281","DOI":"10.37349\/emed.2025.1001281","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): A systemic disease with a variable natural history and challenging management","volume":"6","author":"Adinolfi","year":"2025","journal-title":"Explor. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jgh.12212","article-title":"Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches","volume":"28","author":"Schuppan","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1172\/JCI82204","article-title":"Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver","volume":"125","author":"Satapati","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1194\/jlr.M700505-JLR200","article-title":"Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation","volume":"50","author":"Wang","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9986299","DOI":"10.1155\/2021\/9986299","article-title":"Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD","volume":"2021","author":"Durand","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_8","first-page":"494","article-title":"Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment","volume":"2","author":"Zhang","year":"2021","journal-title":"Explor. Med."},{"key":"ref_9","first-page":"802","article-title":"Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease\/Metabolic Dysfunction-associated Steatotic Liver Disease","volume":"12","author":"Hu","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/liv.13270","article-title":"The therapeutic landscape of non-alcoholic steatohepatitis","volume":"37","author":"Perazzo","year":"2017","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.7326\/M14-0126","article-title":"Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology\/American Heart Association Cholesterol Guideline","volume":"160","author":"Stone","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"McCagg","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","article-title":"Mechanisms for the anti-inflammatory effects of statins","volume":"22","author":"Bu","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, W., Zhao, C., Zhou, J., Zhen, Z., Wang, Y., and Shen, C. (2013). Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076538"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248413489771","article-title":"Increasing Doses of Simvastatin Versus Combined Ezetimibe\/Simvastatin:Effect on Circulating Endothelial Progenitor Cells","volume":"18","author":"Pesaro","year":"2013","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cho, Y., Rhee, H., Kim, Y.-E., Lee, M., Lee, B.-W., Kang, E.S., Cha, B.-S., Choi, J.-Y., and Lee, Y.-H. (2022). Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med., 20.","DOI":"10.1186\/s12916-022-02288-2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14656566.2025.2478917","article-title":"Resmetirom: The first approved therapy for treating metabolic dysfunction associated steatohepatitis","volume":"26","author":"Bhushan","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Machado, M.V., Michelotti, G.A., Xie, G., de Almeida, T.P., Boursier, J., Bohnic, B., Guy, C.D., and Diehl, A.M. (2015). Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease. PLoS ONE, 10, Correction in PLoS ONE 2015, 10, e0132315.","DOI":"10.1371\/journal.pone.0132315"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/cyto.a.23772","article-title":"Nonglucuronidated Ezetimibe Disrupts CD13- and CD64-Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes\/Macrophages","volume":"95","author":"Robenek","year":"2019","journal-title":"Cytom. Part A"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3201873","DOI":"10.1155\/2019\/3201873","article-title":"Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model","volume":"2019","author":"Rodrigues","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1194\/jlr.M053785","article-title":"Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH","volume":"56","author":"Ioannou","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104093","DOI":"10.1016\/j.etap.2023.104093","article-title":"Molecular mechanisms in thioacetamide-induced acute and chronic liver injury models","volume":"99","author":"Ezhilarasan","year":"2023","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxlet.2019.11.005","article-title":"Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids","volume":"319","author":"Kamble","year":"2020","journal-title":"Toxicol. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Flessa, C.-M., Nasiri-Ansari, N., Kyrou, I., Leca, B.M., Lianou, M., Chatzigeorgiou, A., Kaltsas, G., Kassi, E., and Randeva, H.S. (2022). Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415791"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/18\/1700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:41:38Z","timestamp":1791614498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/18\/1700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":29,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15181700"],"URL":"https:\/\/doi.org\/10.3390\/cells15181700","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}